Ed F. Haislmaier, the Preston A. Wells Jr senior research fellow at the Institute for Family Community, and Opportunity at The Heritage Foundation, talks about the impact of new business partnerships on healthcare costs.
Ed F. Haislmaier, the Preston A. Wells Jr senior research fellow at the Institute for Family Community, and Opportunity at The Heritage Foundation, talks about the impact of new business partnerships on healthcare costs.
Transcript
What impact do you see of recent nontraditional mergers and partnerships — CVS-Aetna and Amazon-JP Morgan-Berkshire Hathaway – having on healthcare costs?
I’m keeping an open but skeptical mind about both of those partnerships. I’m not sure about the CVS-Aetna partnership as really creating that much synergy. I’m willing to be persuaded but it just doesn’t seem to be a synergistic approach. The question about Amazon and Berkshire and JP Morgan Chase—that is even less clear. It does seem to have the feel of large employers getting together to finally figure out how to buy smarter, which is something we’ve seen happen before with mixed results.
We’ve had business coalitions on healthcare and things like that. Both of those are very early stages and I’m willing to say that something might happen, but I’m skeptical on both.
The Center for American Progress recently released a framework called Medicare Extra for All, similar to Senator Bernie Sanders’ own proposal — what is your take on these types of proposals?
The basic problem that they’re trying to address is the so-called uninsurance. I’m not sure how many uninsured people we actually have left because functionally most of the people, if people are technically insured, a lot of them are functionally insured. In other words, they have access to care, they’re just not in an insurance program.
This is kind of interesting because we’ve seen this with the Affordable Care Act is we’ve seen people get the Affordable Care Act insurance when they need medical care and then drop it. So, do you count those people as insured or uninsured? Because once they’ve been treated, they drop the insurance.
I think the goal of insurance for everybody, while it sounds nice, is really a secondary. The primary goal I think we need to focus on are people getting access to the medical care that they need. How we do that, how we pay for it, becomes a secondary issue.
The Push for Fair Pricing and Reform in Pharmacy Benefit Management
April 3rd 2025Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to enhance transparency, reduce patient costs, and navigate the evolving healthcare landscape.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Using AI-Driven Strategies to Optimize Specialty Drug Costs, Manage Polypharmacy
April 2nd 2025As health care costs continue to rise, artificial intelligence (AI)-driven solutions are emerging as a powerful tool for managing specialty drug spending and polypharmacy risks, as showcased in recent research presented at the Academy of Managed Care Pharmacy 2025 conference.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
The IRA’s Unintended Consequences for Drug Pricing and Coverage
April 2nd 2025The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.
Read More